People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Pharmaceuticals, Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aeovian Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $125.0M | $297.5M | 2017 |
| Charity Partners Inc. | — | Other | Series A | $20.0M | $178.8M | 2010 |
| Aeglea BioTherapeutics Holdings, LLC | — | Biotechnology | Series A | $15.8M | $387.1M | 2013 |
| Amarantus Bioscience Holdings, Inc. | — | Pharmaceuticals | Seed | $6.0M | $11.4M | 2014 |
| Sequel Pharmaceuticals Inc | — | Pharmaceuticals | Seed | $5.4M | $38.0M | 2009 |
David Lowe at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Lowe on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Powell | 1 | 14 |
| Nina Kjellson | 1 | 11 |
| Robert Harris | 1 | 9 |
| Jens Eckstein | 1 | 8 |
| Richard Gaster | 1 | 7 |
| Anthony K. Tjan | 1 | 6 |
| Ben Zadik | 1 | 6 |
| James Gilbert | 1 | 5 |
| Joseph Turner | 1 | 4 |
| Robert Farrell | 1 | 4 |
| Henry Skinner | 1 | 4 |
| Robert L. Harris | 1 | 4 |
| Stuart J.M. Collinson | 1 | 4 |
| James Peyer | 1 | 3 |
| Eckard Weber | 1 | 3 |
| Armen Shanafelt | 1 | 3 |
| Daniel K. Turner, III | 1 | 2 |
| Marc Faerber | 1 | 2 |
| Howard C. Dittrich | 1 | 2 |
| Randall Woods | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.